Reig Jofre submits results note on second quarter of 2022

REIG JOFRE’s revenues grew by 14% grew by and EBITDA grew by 6% in the first half of the year

REIG JOFRE closes the best first half of its history with 132 million revenues, driven by the recovery of the global antibiotic market.  The new injectable products plant in Barcelona begins manufacturing products developed by REIG JOFRE.

At the end of June, listed company REIG JOFRE achieved €132 million in sales, a 14% increase over the same period of the previous year. In addition to the increased demand for antibiotics manufactured in the plant in Toledo, there is the start of industrial manufacturing in the new plant in Barcelona and a strong growth in Consumer Healthcare sales. EBITDA grew by 6%, reaching 14.2 M€ which is also a record result in a semester.

The Pharmaceutical Technologies division, devoted to injectable and antibiotic products, is the leader of this growth, while the growth of the previous year in the Specialty Pharmacare division, focused on prescription medical products, has slowed down. Consumer Healthcare, the consumer products division, continues with strong growth, particularly in the FORTE PHARMA, brand in French and Belgian markets.

Download the full document (PDF)